Clinical trials: Chemo Fog
Chemotherapy-Related Cognitive Impairment
Biomarkers for Chemotherapy Associated Neurotoxicity
To assess if biomarkers can be used to predict early treatment related neurotoxicity in patients with Acute lymphoblastic leukaemia (ALL) or lymphoblastic lymphoma (LBL) and to inform development of novel interventions.
- Trial name
- BioCAN (NCT05280262)
- Testing
- CogState Test
- Where
- United Kingdom
- Volunteers
- 200 people
- Sponsor
- NHS Greater Glasgow and Clyde
Breast Cancer Females, Oncology
Effects of a Group Versus Individual Cognitive Training Program on Chemotherapy-induced Cognitive Impairment (Chemobrain) in Breast Cancer Patients Undergoing Active Treatment
Introduction: The significant improvement in breast cancer survival, largely attributable to biomedical and technological progress, makes it increasingly necessary to investigate the secondary effects linked to this pathology.
- Trial name
- NCT07165912
- Testing
- Health Education Program, Individual Cognitive Training Program, Group training program
- Where
- 2 sites in Spain
- Volunteers
- 75 people
- Sponsor
- University of Salamanca
Survivors of Childhood Cancer
Technological Gaming in Cancer Survivors (WINNERS)
HYPOTHESIS 1. Neurocognitive deficits in cancer survivors are underestimated. They represent a very limiting long-term side effect in this group of patients. 2.
- Trial name
- WINNERS (NCT06312969)
- Testing
- Video game based training
- Where
- Spain
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Antonio Pérez Martínez
Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity
Investigating Cognitive Impairment in Young Patients With Cancer Prospectively
The MyBrain study investigates the brain function of children, adolescents and young adults during and after chemo treatment for cancer.
- Conditions
- Chemotherapy-Related Cognitive Impairment, Chemotherapeutic Toxicity, Chemo-brain, Cancer
- Trial name
- MyBrain (NCT05840575)
- Where
- Denmark
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Oncology, Support Care
Breast Cancer and Chemobrain : Effects of Photobiomodulation on the Improvement of Perceived Cognitive Impairment
Breast cancer is one of the most common cancers in metropolitan France, with over 60,000 new cases in 2023. Mostly a female cancer, it can affect a young population, with around 20% of breast cancers occurring in women under 50.
- Conditions
- Oncology, Support Care, Cognitive Disorders
- Trial name
- REGAIN (NCT06995443)
- Testing
- Photobiomodulation
- Where
- France
- Volunteers
- 200 people
- Sponsor
- Centre Hospitalier de Valenciennes